CorVista Health Appoints Charles R. Bridges as Chief Scientific Officer

CorVista Health, Inc., a digital health company dedicated to improving cardiovascular disease diagnosis, announces the appointment of Charles R. Bridges, M.D., Sc.D., as Executive Vice President and Chief Scientific Officer.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, January 18, 2022
Information
Tags: 
Science, Cardiology, Radiology, Research, Pharmaceutical, Health, Fitness & Nutrition, Clinical Trials, Computer science, Applied physics, Patient, NIH, University, Mortality, Biological engineering, Exercise, FEC v. Wisconsin Right to Life, Inc., Electrical engineering, Harvard Medical School, Janssen Pharmaceuticals, National Institutes of Health, Degenerative disease, Injection, Â, Radiation, Department, Massachusetts Institute of Technology, Harvard–MIT Program in Health Sciences and Technology, University of North Carolina at Pembroke, View, Physics, Cardiovascular disease, Fasting, National, Circulatory system, Diagnosis, Harvard College, MD, Chemical engineering, Multimedia, Health care analytics, Pennsylvania Hospital, Professor, JNJ, Physician, Investment, Machine learning, Management, Medical device, Engineering, Science, Technology
Geotags: 
PENNSYLVANIA, TORONTO, SC, NORTH CAROLINA
⚠generated by AI ↴
Summary
Key Points: 
  • CorVista Health, Inc., a digital health company dedicated to improving cardiovascular disease diagnosis, announces the appointment of Charles R. Bridges, M.D., Sc.D., as Executive Vice President and Chief Scientific Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220118005335/en/
    Dr. Charles Bridges, Chief Scientific Officer and Executive Vice President, CorVista Health.
  • His experience and vast clinical knowledge will be instrumental in getting our novel technology to market, said Don Crawford, President and Chief Executive Officer, CorVista Health.
  • I joined CorVista Health as I believe the CorVista System will be a revolutionary technology in aiding physicians to better diagnose cardiovascular disease, said Dr. Bridges.


CorVista Health, Inc., a digital health company dedicated to improving cardiovascular disease diagnosis, announces the appointment of Charles R. Bridges, M.D., Sc.D., as Executive Vice President and Chief Scientific Officer. In this role Charles will lead the scientific and clinical development of the CorVista System for commercialization.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220118005335/en/

Dr. Charles Bridges, Chief Scientific Officer and Executive Vice President, CorVista Health. (Photo: Business Wire)

Dr. Charles Bridges, Chief Scientific Officer and Executive Vice President, CorVista Health. (Photo: Business Wire)

“We are thrilled to have Charles join our executive team. His experience and vast clinical knowledge will be instrumental in getting our novel technology to market,” said Don Crawford, President and Chief Executive Officer, CorVista Health. “In his new role, Charles will provide strategic insight into scientific and clinical development which will be crucial as we focus on commercialization.”

Dr. Bridges was the first African American Full Professor of Surgery at the University of Pennsylvania and a member of the Bioengineering Graduate Group, Chief of Cardiac Surgery at Pennsylvania Hospital, and Professor and Chairman of the Department of Cardiothoracic and Vascular Surgery at Carolina’s HealthCare System with the University of North Carolina. Dr. Bridges received more than $10 million in continuous National Institutes of Health (NIH) RO1 funding, has over 170 peer-reviewed publications and 15 patents.

“I joined CorVista Health as I believe the CorVista System will be a revolutionary technology in aiding physicians to better diagnose cardiovascular disease,” said Dr. Bridges. “Once I learned about the CorVista System, I immediately appreciated the unique opportunity it presents to leverage my clinical, technical and leadership skills to improve the diagnosis and treatment of cardiovascular disease, the leading cause of mortality globally.”

Most recently, Dr. Bridges was Chief Technology Officer and Head of Cross Enterprise Innovation for the Cardiovascular and Pulmonary Hypertension Therapeutic Areas at Janssen Pharmaceuticals, of Johnson and Johnson, Inc (JNJ). At JNJ he served as the scientific lead on multiple cardiovascular and neurovascular device equity investments and acquisitions. He spearheaded the development of novel therapeutic and diagnostic devices and applications of advanced data sciences. In 2021, he received the JNJ, enterprise wide, Juan A. Simpson Outstanding Employee Service Award for “excellence both personally and professionally”.

Dr. Bridges received his Bachelors Degree in Engineering and Applied Physics from Harvard College magna cum laude, entering Harvard Medical School at age 18 in the Harvard-MIT Program in Health Sciences and Technology, receiving the MD degree with honors. He received a Master of Science in Electrical Engineering and Computer Science and a Doctor of Science in Chemical Engineering from the Massachusetts Institute of Technology.

About CorVista® System

CorVista System is a non-invasive point-of-care solution that is intended to synchronously collect and apply machine learning to a patient’s cardiac and hemodynamic signals to predict the likelihood of cardiovascular diseases without the use of radiation, contrast agents, injections, fasting or exercise. Within minutes of the test, the CorVista® Analysis is available in a secure web portal to aid physicians in rapidly diagnosing and treating patients with suspected cardiovascular disease, answering important clinical questions to better guide treatment decisions. CorVista System is an investigational device limited by federal law to investigational use. CorVista System is not available for commercial distribution.

About CorVista® Health

CorVista Health, Inc. is a subsidiary of Toronto-based Analytics For Life Inc. CorVista Health is applying machine learning using real world test data to develop a novel cardiac analysis platform, CorVista® System, with the aim of transforming cardiovascular care and the patient experience. For more information, visit www.corvista.com.

Copyright: 
Copyright Business Wire 2022